Acronym:
SADAL
ACTRN/NCT /ethics:
KCP-330-009
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Lymphoma | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Lymphoma |
| Age Range | 18 years and older | Cancer Stage | All stages |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Lymphoma |
| Cancer Stage | All stages |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A Phase 2b open-label study of selinexor in patients with relapsed/ refractory diffuse large B-cell lymphoma. Selinexor against diffuse aggressive lymphoma.
Lay Summary
Sponsor / Cooperative group
KaryoPharm
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Ashford Cancer Centre Research | Helen Daykin | hdaykin@adelaidecancercentre.com.au | 08 8292 2240 | Not Yet Recruiting |